Uterine Transposition: Feasibility Study
Launched by HOSPITAL ERASTO GAERTNER · Jan 31, 2017
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
Patients with pelvic cancer frequently require radiotherapy, which causes infertility even at low doses. Oocytes are highly sensitive to radiation, as a dose of 2 Gy is able to destroy up to 50% of the oocyte population.
Pelvic radiotherapy with fertility preservation is not yet available for women with pelvic tumors. In such cases, the only options are egg and/or embryo freezing and ovarian transposition (OT), which might preserve reproductive and hormonal function, respectively. While ovarian tissue cryopreservation and transplantation are possible, they are still experimental.
Uterine ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with pelvic cancer and indication for pelvic radiation therapy who have fertility sparing desire.
- Exclusion Criteria:
- • Previously documented infertility, ovarian failure or gynecologic cancer.
- • More than 40 yo.
- • Previous oophorectomy
- • Tumor infiltrating uterus or adnexes
- • Presence of peritoneal metastasis
- • Presence of systemic metastasis
- • Previous retroperitoneal radiotherapy
- • Retroperitoneal radiotherapy planned
About Hospital Erasto Gaertner
Hospital Erasto Gaertner is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a strong emphasis on oncology and specialized patient care, the hospital combines state-of-the-art facilities with a multidisciplinary team of experts to conduct rigorous clinical studies. Committed to ethical standards and patient safety, Hospital Erasto Gaertner fosters collaboration among researchers, healthcare professionals, and patients, aiming to translate scientific discoveries into effective treatment options. Its robust research infrastructure and focus on personalized medicine position it as a pivotal player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Curitiba, Parana, Brazil
Patients applied
Trial Officials
Reitan Ribeiro, MD
Principal Investigator
Erasto Gaertner Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials